Indaptus Therapeutics Announces New Data From Ongoing Phase 1 Trial Of Decoy20; Latest Data From First And Second Cohorts Support Company's 'Pulse-Prime' Approach, Demonstrating Rapid Clearance, Broad Immune Activation, And Encouraging Safety Profile
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics announced new data from its ongoing Phase 1 trial of Decoy20, showing rapid clearance, broad immune activation, and an encouraging safety profile. The data were presented at the ASCO Annual Meeting.
June 03, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indaptus Therapeutics announced promising new data from its Phase 1 trial of Decoy20, demonstrating rapid clearance, broad immune activation, and an encouraging safety profile. This data was presented at the ASCO Annual Meeting.
The positive data from the Phase 1 trial of Decoy20, including rapid clearance and broad immune activation, is likely to boost investor confidence and positively impact the stock price in the short term. The presentation at a prestigious event like the ASCO Annual Meeting further validates the significance of these findings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100